The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.

Gilead presented the data at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). Image credit: Shutterstock / Sundry Photography Gilead is set to launch a Phase III trial of its ...

Overall survival data was not yet mature with less than a quarter of the required number of events having occurred. Credit: Shutterstock / Maria Sbytova. Pharma giant Pfizer and Arvinas’s human ...

J&J and Protagonist Therapeutics are collectively developing icotrokinra, which is poised to be an immunology blockbuster. Image credit: Emily frost / Shutterstock. Johnson & Johnson (J&J) and ...

AstraZeneca has reported positive “high-level” outcomes from the Phase III MATTERHORN trial of Imfinzi (durvalumab) with FLOT chemotherapy.

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

The Phase II and Phase III trials show the therapy is effective at dropping blood pressure. Image credit: Good dreams – Studio / Shutterstock. Mineralys Therapeutics’s oral hypertension therapy, ...

The trial is structured for enrolling nearly 350 subjects. Credit: Joyseulay/Shutterstock. PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to ...

The company’s stock, listed on the Copenhagen market, dropped by 9% on the news, from a DKr598 ($86.91) market open on 0 March to a DKr544 low. Credit: Shutterstock / JHVEPhoto. Novo Nordisk’s ...

The company announced that at week 16, more than 83% of patients dosed with Ebglyss no longer required the use of concomitant therapies such as topical corticosteroids. Credit: Shutterstock / Kmpzzz.

Persica's antibiotic-based drug could benefit patients with chronic lower back pain who are suffering from an infection in ...

Everest Medicines has dosed the first subject with EVM16, the company’s personalised mRNA cancer vaccine, in the EVM16CX01 ...